Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00123942 · ClinicalTrials.gov registry record · Phase 1
Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease
A Phase 1 study, sponsored by MedImmune.
- Terminated
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT00123942 is a Phase 1 study that was terminated before completion, run by MedImmune. The registered enrollment target is 31 participants.
The verdict
NCT00123942, a Phase 1 study, was terminated before completion, sponsored by MedImmune.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the maximum tolerated dose (MTD) and safety and tolerability of MEDI-507 in patients with CD2-positive lymphoproliferative disorders.
Interventions
- DRUG MEDI-507
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2004-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00123942
The ClinicalTrials.gov registry entry for NCT00123942 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MEDI-507 is the first listed.
NCT00123942 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00123942 about?
NCT00123942 is a clinical study titled "Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease". The primary objective of this study is to determine the maximum tolerated dose (MTD) and safety and tolerability of MEDI-507 in patients with CD2-positive lymphoproliferative disorders.
What is the current status of trial NCT00123942?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2004-04.
What interventions are being tested in trial NCT00123942?
The interventions under investigation include: MEDI-507 (DRUG).
Who is sponsoring clinical trial NCT00123942?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.